pyrazines has been researched along with ly2603618 in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (83.33) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, SP; Donehower, RC; Hurt, K; Hynes, SM; Iyengar, T; Lewandowski, K; McKane, S; Ramanathan, RK; Weiss, GJ; Westin, E | 1 |
| Buck, SA; Caldwell, JT; Edwards, H; Ge, Y; Qing, WY; Taub, JW; Wang, G; Wang, Z | 1 |
| Barda, D; Barnard, D; Blosser, W; Clawson, D; Cox, K; Diaz, H; Guo, S; King, C; Marshall, M | 1 |
| Abraham, TL; Cassidy, KC; Chana, E; Hynes, SM; Jost, LM; Mitchell, MI; Palmieri, MD; Rehmel, JF; Wickremsinhe, ER | 1 |
| Cui, YJ; Fei, HR; Li, ZM; Sun, BL; Sun, YK; Wang, FZ; Wang, XY; Yang, XY; Zhang, JG | 1 |
| Barnard, D; Calles, A; Calvo, E; Chen, VJ; Diaz, HB; Dickgreber, N; Huber, L; Hynes, SM; Iversen, P; Kays, L; Kumm, E; Lin, AB; Marshall, M; Merzoug, FF; Ohnmacht, U; Sebastian, M; Voss, B; Wehler, T | 1 |
| Chandler, J; Decker, R; Hynes, SM; Mitchell, M; Ott, J; Wickremsinhe, E; Zhang, W | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M | 1 |
| Edwards, H; Ge, Y; Li, X; Lin, H; Niu, X; Taub, JW; Wang, G; Wang, Y; Zhao, J | 1 |
| Deng, O; Du, Z; Gao, J; Gorityala, S; Lai, J; Ma, Z; Susana, G; Xiong, X; Xu, Y; Yan, C; Yang, S; Zhang, J; Zhang, Y | 1 |
| Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Hasvold, G; Hauge, S; Joel, M; Juzenas, P; Naucke, C; Rødland, GE; Stokke, T; Syljuåsen, RG | 1 |
| Benes, CH; Borgmann, K; Dinkelborg, PH; Gheorghiu, L; Gurski, JM; Hong, TS; Jimenez, RB; Juric, D; Wang, M; Willers, H | 1 |
| Bajzikova, M; Boukalova, S; Coelho, A; Davidova, E; Ditzel, HJ; Hubackova, S; Kovarova, J; Neuzil, J; Rohlena, J; Terp, MG | 1 |
| Ju, JQ; Li, XH; Pan, MH; Sun, MH; Sun, SC; Xu, Y | 1 |
| Arthur, J; Conti, DJ; Friedrich, TD; Hainley, LE; Hayner-Buchan, A; Hughson, MS; Lehman, JM; Narendran, A; Smith, R | 1 |
6 trial(s) available for pyrazines and ly2603618
| Article | Year |
|---|---|
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2013 |
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA; Female; Glutamates; Guanine; Humans; Male; Mice, Nude; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Pyrazines; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Checkpoint Kinase 1; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Female; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinases; Pyrazines; Young Adult | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Checkpoint Kinase 1; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
12 other study(ies) available for pyrazines and ly2603618
| Article | Year |
|---|---|
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neuroblastoma; Panobinostat; Phenylurea Compounds; Protein Kinases; Pyrazines | 2013 |
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Doxorubicin; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Tumor Suppressor Protein p53 | 2014 |
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
Topics: Administration, Intravenous; Aged; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Feces; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Neoplasms; Phenylurea Compounds; Pyrazines; Tandem Mass Spectrometry | 2014 |
The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Topics: Antineoplastic Agents; Antirheumatic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Chloroquine; DNA Damage; DNA Repair; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Serine | 2014 |
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; THP-1 Cells; U937 Cells | 2016 |
Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; DNA Repair; Homologous Recombination; Humans; MCF-7 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes; Urea | 2016 |
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Topics: A549 Cells; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinases; DNA Damage; DNA Replication; Drug Synergism; Flow Cytometry; Humans; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Pyrimidinones; S Phase; Thiophenes; Urea | 2017 |
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Topics: Adenocarcinoma of Lung; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Leukemic; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Triple Negative Breast Neoplasms | 2019 |
Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 1; Dihydroorotate Dehydrogenase; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; HCT116 Cells; Humans; Leflunomide; MCF-7 Cells; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Oxidoreductases Acting on CH-CH Group Donors; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Ribosomes; Signal Transduction; Tumor Suppressor Protein p53 | 2020 |
CHK1 monitors spindle assembly checkpoint and DNA damage repair during the first cleavage of mouse early embryos.
Topics: Animals; Apoptosis; Aurora Kinase B; Cell Cycle Proteins; Checkpoint Kinase 1; Chromosome Segregation; DNA Damage; DNA Repair; Embryo, Mammalian; Embryonic Development; Kinetochores; M Phase Cell Cycle Checkpoints; Mice; Microtubules; Oxidative Stress; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyrazines; Reactive Oxygen Species | 2020 |
Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection.
Topics: BK Virus; Cells, Cultured; Checkpoint Kinase 1; DNA Damage; DNA Repair; Humans; Kidney; Kidney Transplantation; Phenylurea Compounds; Polyomavirus Infections; Pyrazines; Tumor Virus Infections; Virus Replication | 2021 |